<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00051662</url>
  </required_header>
  <id_info>
    <org_study_id>HUPA600</org_study_id>
    <nct_id>NCT00051662</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XOMA (US) LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XOMA (US) LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a humanized monoclonal antibody&#xD;
      (efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II, randomized, double-blind, placebo-controlled study to:&#xD;
&#xD;
        1. Demonstrate the clinical efficacy of efalizumab in the treatment of subjects with&#xD;
           psoriatic arthritis (PsA).&#xD;
&#xD;
        2. Evaluate the safety, tolerability and pharmacokinetics of efalizumab in the treatment of&#xD;
           subjects with PsA&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date>February 2004</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>45</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efalizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosed with PsA as defined by:&#xD;
&#xD;
               -  Presence of psoriasis with at least one 2 cm plaque AND&#xD;
&#xD;
               -  One of the five functional classifications of PsA&#xD;
&#xD;
          -  Functional Class I, II, or III as defined by the ACR Classification of Functional&#xD;
             Status in Rheumatoid Arthritis&#xD;
&#xD;
          -  Moderate to severe disease, defined as follows:&#xD;
&#xD;
               -  At least 3 tender and 3 swollen joints (78 joint count for tenderness and 76&#xD;
                  joints for swelling; AND&#xD;
&#xD;
               -  Either ESR ≥ 28 mm/hr, CRP ≥ 1.5 mg/dL, or morning stiffness for ≥ 30 minutes.&#xD;
&#xD;
          -  Currently taking at least one of the following systemic therapies for PsA:&#xD;
             pre-existing stable doses of NSAIDs, corticosteroids (≤ 10 mg/day), and either&#xD;
             sulfasalazine (≤ 3 gm/day) or methotrexate (≥ 7.5 and ≤ 30 mg/week) but not both.&#xD;
&#xD;
          -  18 to 80 years of age.&#xD;
&#xD;
          -  Body weight ≤ 125 kg (275 lbs).&#xD;
&#xD;
          -  Candidate for systemic immunomodulatory therapy.&#xD;
&#xD;
          -  Using an acceptable method of birth control.&#xD;
&#xD;
          -  If female, must have a negative serum pregnancy test during screening period, must be&#xD;
             surgically sterile, or must be at least five years postmenopausal.&#xD;
&#xD;
          -  Informed about the study and signed an informed consent prior to performance of any&#xD;
             study-related procedure.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Previous treatment with efalizumab.&#xD;
&#xD;
          -  Rheumatoid Factor positive without dactylitis or positive X-rays of the hands or feet,&#xD;
             or with rheumatoid nodules.&#xD;
&#xD;
          -  History of joint replacement surgery within 60 days prior to the start of study drug&#xD;
             dosing.&#xD;
&#xD;
          -  Joint replacement therapy planned within nine months subsequent to the start of study&#xD;
             drug dosing.&#xD;
&#xD;
          -  Intra-articular cortisone injections within 28 days prior to the start of study drug&#xD;
             dosing.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies. Respiratory distress (dyspnea, oxygen desaturation with pO2 &lt; 90% or onset&#xD;
             of acute respiratory distress syndrome), flank or back pain, and/or hypotension may be&#xD;
             signs of anaphylaxis.&#xD;
&#xD;
          -  Active bacterial, viral, fungal, mycobacterium tuberculosis or atypical mycobacterium&#xD;
             infection.&#xD;
&#xD;
          -  Positive PPD test unless subject with positive PPD test completed a course of&#xD;
             treatment for tuberculosis&#xD;
&#xD;
          -  History of any opportunistic infection.&#xD;
&#xD;
          -  History of a malignancy within the past five years. Subjects with a history of fully&#xD;
             resolved, resected, basal or squamous cell carcinoma may be enrolled.&#xD;
&#xD;
          -  Received any vaccine within 28 days prior to the start of study drug dosing.&#xD;
&#xD;
          -  Chronic disorders apart from PsA affecting the joints, such as systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, gout, scleroderma or known reactive arthritis&#xD;
             (e.g., Reiter's syndrome).&#xD;
&#xD;
          -  COPD, asthma, or other pulmonary disease requiring more therapy than using one inhaler&#xD;
             4× daily.&#xD;
&#xD;
          -  Failed to respond or maintain response to Enbrel.&#xD;
&#xD;
          -  Received any DMARD other than methotrexate or sulfasalazine during the 28 days prior&#xD;
             to the start of study drug dosing.&#xD;
&#xD;
          -  Approved biologic PsA therapy during the 28 days or seven half-lives of the drug prior&#xD;
             to the start of study drug dosing, whichever is the greater length of time; Enbrel&#xD;
             within 42 days prior to the start of study drug dosing.&#xD;
&#xD;
          -  Investigational drug and/or treatment during the 28 days or 7 half-lives of the drug&#xD;
             prior to the start of study drug dosing, whichever is the greater length of time.&#xD;
&#xD;
          -  Any condition which, in the opinion of the Investigator, would jeopardize the&#xD;
             subject's safety following exposure to efalizumab.&#xD;
&#xD;
          -  Liver disease (e.g., hepatitis, cirrhosis) or abnormal hepatic function (AST or ALT ≥&#xD;
             2.5&#xD;
&#xD;
               -  ULN).&#xD;
&#xD;
          -  Serum creatinine level ≥ 1.5 mg/dL&#xD;
&#xD;
          -  Platelet count ≤ 125,000 cells/mm3&#xD;
&#xD;
          -  WBC count ≤ 3,500 cells/mm3&#xD;
&#xD;
          -  Total lymphocyte count ≤ 1000 cells/mm3&#xD;
&#xD;
          -  Seropositive for hepatitis B&#xD;
&#xD;
          -  Seropositive for hepatitis C antibody&#xD;
&#xD;
          -  Seropositive for HIV&#xD;
&#xD;
          -  Antinuclear antibodies titer ≥ 1:80&#xD;
&#xD;
          -  History of inflammatory bowel disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2004</verification_date>
  <study_first_submitted>January 14, 2003</study_first_submitted>
  <study_first_submitted_qc>January 15, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2003</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

